Corvus Pharmaceuticals (CRVS) Enterprise Value (2015 - 2026)
Corvus Pharmaceuticals (CRVS) posted quarterly Enterprise Value of -$236.7 million for Q1 2026, down 4635.23% year-over-year from $5.2 million in Q1 2025, and down 317.12% quarter-over-quarter from -$56.8 million in Q4 2025.
Corvus Pharmaceuticals (CRVS) Enterprise Value (2015 - 2026) Analysis & Trends
Corvus Pharmaceuticals' Enterprise Value history runs 12 years deep, the most recent figure standing at -$236.7 million for Q1 2026.
- In Q1 2026, Enterprise Value fell 4635.23% year-over-year to -$236.7 million; the TTM figure through Mar 2026 stood at -$236.7 million (down 4635.23% YoY), while the FY2025 annual figure was -$56.8 million, down 9.21% from the prior year.
- Enterprise Value for Q1 2026 stood at -$236.7 million, down from -$56.8 million in the prior quarter.
- The five-year high for Enterprise Value was -$2.9 million in Q3 2025, with the low at -$236.7 million in Q1 2026.
- The 5-year median for Enterprise Value is -$14.7 million (2025), against an average of -$31.9 million.
- The sharpest annual moves came in 2022 and 2026: Enterprise Value surged 79.26% in 2022, then sank 4635.23% in 2026.
- Corvus Pharmaceuticals' Enterprise Value stood at -$13.2 million in 2022, then advanced by 4.1% to -$12.6 million in 2023, then slumped by 311.76% to -$52.0 million in 2024, then decreased by 9.21% to -$56.8 million in 2025, then plunged by 317.12% to -$236.7 million in 2026.
- Business Quant data shows CRVS's Enterprise Value at -$236.7 million in Q1 2026, -$56.8 million in Q4 2025, and -$2.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | -5.18 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -3.94 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -8.46 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 2.12 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -3.31 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.16 Bn |
| 10 | Corvus Pharmaceuticals | 1.25 Bn | 1.04 Bn | - | -215.23 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -215.23 Mn |
| Mar 31, 2026 | -236.71 Mn |
| Dec 31, 2025 | -56.75 Mn |
| Sep 30, 2025 | -2.87 Mn |
| Jun 30, 2025 | -14.69 Mn |
| Mar 31, 2025 | -5.00 Mn |
| Dec 31, 2024 | -51.96 Mn |
| Sep 30, 2024 | -4.68 Mn |
| Jun 30, 2024 | -14.84 Mn |
| Mar 31, 2024 | -7.46 Mn |
| Dec 31, 2023 | -12.62 Mn |
| Sep 30, 2023 | -20.11 Mn |
| Jun 30, 2023 | -7.66 Mn |
| Mar 31, 2023 | -9.65 Mn |
| Dec 31, 2022 | -13.16 Mn |
| Sep 30, 2022 | -24.59 Mn |
| Jun 30, 2022 | -28.48 Mn |
| Mar 31, 2022 | -31.46 Mn |
| Dec 31, 2021 | -63.46 Mn |
| Sep 30, 2021 | -72.30 Mn |